Literature DB >> 15012028

Is there a change in cytomegalovirus seroepidemiology in Spain?

F de Ory1, R Ramírez, L García Comas, P León, M J Sagües, J C Sanz.   

Abstract

The aim of this paper is to compare the seroprevalence of cytomegalovirus (CMV) in women in the Autonomous Region of Madrid (ARM) obtained in two different years (1993 and 1999), according to age and seroprevalence of a virus transmitted by the faecal-oral route (hepatitis A virus, HAV) and another virus of respiratory transmission (varicella zoster virus, VZV). A total of 1813 serum samples were studied, taken from females aged 2-40 in two different serosurveys which were representative of the general population in the ARM. Of these, 933 were taken in 1993, and 880 in 1999. In each survey the samples were distributed over six groups, according to age group (2-5, 6-10, 11-15, 16-20, 21-30 and 31-40 years). CMV- and VZV-specific IgG was tested by indirect ELISA (Dade-Behring, Germany); and HAV-IgG by ImX (Abbott, USA) in the 1993 samples, or by Vidas (BioMérieux, France) in the case of those taken in 1999. A significant age-related rise in CMV seroprevalence was observed in both serosurveys. The seroprevalence obtained was lower in all age groups in 1999 than in 1993. The differences were statistically significant in two age groups: 6-10 years old (43.7 vs. 56.7%) and 31-40 years old (79.1 vs. 90.3%). In the younger age groups concurrent seroprevalence of CMV and VZV was significant lower in 1999. In older age groups a significant decrease in concurrent seroprevalence of both CMV and HAV was also seen. Agreement between serological results for CMV-HAV, CMV-VZV and HAV-VVZ during the two time periods and in every age group was poor or fair (kappa index < or = 0.2 or between 0.21 and 0.4) in all age groups. To conclude, a change in CMV epidemiology seems to be taking place in Madrid. The increase in the proportion of CMV seronegative women of childbearing age may have some impact on the incidence of congenital diseases related to vertical transmission of CMV. Apparently, such a change, among children, could be related to a lower close contact transmission rate (as in VZV), and among adults to improvements in standards of public health (as in HAV). However, due to the poor or fair agreement between serological results for CMV-HAV, CMV-VZV and HAV-VVZ, other independent factors may affect the fall in CMV seroprevalence.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15012028     DOI: 10.1023/b:ejep.0000013253.56343.6f

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  14 in total

1.  Trends in the epidemiology of herpes simplex virus type 1 among the young adult population in Israel.

Authors:  J Katz; M Gdalevitz; I Ashkenazi; J Shemer
Journal:  Infection       Date:  1999       Impact factor: 3.553

2.  Effect of human sex hormones on cytomegalovirus growth and Fc receptor expression.

Authors:  P A Mackowiak; M L Haley; M Marling-Cason; K M Tiemens; J P Luby
Journal:  J Lab Clin Med       Date:  1987-10

3.  Cytomegalovirus reinfection in young children.

Authors:  J F Bale; S J Petheram; I E Souza; J R Murph
Journal:  J Pediatr       Date:  1996-03       Impact factor: 4.406

4.  [Cytomegalovirus seroepidemiology in the community of Madrid].

Authors:  F de Ory Manchón; J C Sanz Moreno; R Castañeda López; R Ramírez Fernández; P León Rega; I Pachón del Amo
Journal:  Rev Esp Salud Publica       Date:  2001 Jan-Feb

5.  Humoral and cell-mediated immune responses to herpesvirus antigens during pregnancy--a longitudinal study.

Authors:  A Kumar; D L Madden; G A Nankervis
Journal:  J Clin Immunol       Date:  1984-01       Impact factor: 8.317

6.  Seroprevalence of herpes simplex virus types 1 and 2 and cytomegalovirus in adolescents.

Authors:  S L Rosenthal; L R Stanberry; F M Biro; M Slaoui; M Francotte; M Koutsoukos; M Hayes; D I Bernstein
Journal:  Clin Infect Dis       Date:  1997-02       Impact factor: 9.079

7.  Summary of the International Consensus Symposium on Advances in the Diagnosis, Treatment and Prophylaxis and Cytomegalovirus Infection.

Authors:  J T van der Meer; W L Drew; R A Bowden; G J Galasso; P D Griffiths; D A Jabs; C Katlama; S A Spector; R J Whitley
Journal:  Antiviral Res       Date:  1996-11       Impact factor: 5.970

8.  [A change in the epidemiologic pattern of hepatitis A in Spain].

Authors:  L Salleras; M Bruguera; J Vidal; J L Taberner; P Plans; M T Jiménez de Anta; J Rodés
Journal:  Med Clin (Barc)       Date:  1992-06-13       Impact factor: 1.725

9.  Trends in hepatitis A virus infection with reference to the process of urbanization in the greater Madrid area (Spain).

Authors:  C Amela; I Pachón; R Bueno; C de Miguel; F Martinez-Navarro
Journal:  Eur J Epidemiol       Date:  1995-10       Impact factor: 8.082

Review 10.  Transfusion-associated cytomegalovirus infections.

Authors:  S P Adler
Journal:  Rev Infect Dis       Date:  1983 Nov-Dec
View more
  19 in total

1.  Cytomegalovirus (CMV) seroprevalence in pregnant women, bone marrow donors and adolescents in Germany, 1996-2010.

Authors:  Gisela Enders; Anja Daiminger; Lisa Lindemann; Frank Knotek; Ursula Bäder; Simone Exler; Martin Enders
Journal:  Med Microbiol Immunol       Date:  2012-03-08       Impact factor: 3.402

2.  Incidence of cytomegalovirus infection in Shanghai, China.

Authors:  Feng-Qin Fang; Qi-Shi Fan; Zhi-Jun Yang; Yi-Bing Peng; Li Zhang; Ke-Zi Mao; Yue Zhang; Yu-Hua Ji
Journal:  Clin Vaccine Immunol       Date:  2009-09-23

3.  Epidemiology of human cytomegalovirus (HCMV) in an urban region of Germany: what has changed?

Authors:  Paul R Lübeck; Hans Wilhelm Doerr; Holger F Rabenau
Journal:  Med Microbiol Immunol       Date:  2009-12-01       Impact factor: 3.402

4.  Changing patterns of cytomegalovirus seroprevalence among pregnant women in Norway between 1995 and 2009 examined in the Norwegian Mother and Child Cohort Study and two cohorts from Sor-Trondelag County: a cross-sectional study.

Authors:  Maria Lisa Odland; Kristin M Strand; Svein Arne Nordbø; Siri Forsmo; Rigmor Austgulen; Ann-Charlotte Iversen
Journal:  BMJ Open       Date:  2013-09-27       Impact factor: 2.692

5.  Seroprevalence of cytomegalovirus infection in France in 2010.

Authors:  D Antona; A Lepoutre; L Fonteneau; C Baudon; F Halftermeyer-Zhou; Y LE Strat; D Lévy-Bruhl
Journal:  Epidemiol Infect       Date:  2017-02-07       Impact factor: 4.434

6.  Impact of socioeconomic risk factors on the seroprevalence of cytomegalovirus infections in a cohort of pregnant Polish women between 2010 and 2011.

Authors:  W Wujcicka; Z Gaj; J Wilczyński; W Sobala; E Spiewak; D Nowakowska
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-06-06       Impact factor: 3.267

7.  Sociodemographic factors associated with IgG and IgM seroprevalence for human cytomegalovirus infection in adult populations of Pakistan: a seroprevalence survey.

Authors:  Saira Ibrahim; Anwar A Siddiqui; Amna R Siddiqui; Waquaruddin Ahmed; Paul A H Moss; El-Nasir M A Lalani
Journal:  BMC Public Health       Date:  2016-10-22       Impact factor: 3.295

8.  CMV latent infection improves CD8+ T response to SEB due to expansion of polyfunctional CD57+ cells in young individuals.

Authors:  Alejandra Pera; Carmen Campos; Alonso Corona; Beatriz Sanchez-Correa; Raquel Tarazona; Anis Larbi; Rafael Solana
Journal:  PLoS One       Date:  2014-02-12       Impact factor: 3.240

9.  Predictive factors of cytomegalovirus seropositivity among pregnant women in Paris, France.

Authors:  Dieynaba S N'Diaye; Yazdan Yazdanpanah; Anne Krivine; Thibaut Andrieu; Flore Rozenberg; Olivier Picone; Vassilis Tsatsaris; François Goffinet; Odile Launay
Journal:  PLoS One       Date:  2014-02-24       Impact factor: 3.240

10.  Cytomegalovirus Seroprevalence Among Children and Adolescents in Germany: Data From the German Health Interview and Examination Survey for Children and Adolescents (KiGGS), 2003-2006.

Authors:  Sebastian Voigt; Angelika Schaffrath Rosario; Annette Mankertz
Journal:  Open Forum Infect Dis       Date:  2015-12-09       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.